Results for "Yorvipath Treatment Options"
Ads
Web Results
Yorvipath Approved for Treatment of Hypoparathyroidism - eMPR.com
www.empr.com
Aug 12, 2024 ... The Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in ...
www.empr.com
Aug 12, 2024 ... The Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in ...
Yorvipath® - Drug Review - Iowa Medicaid PDL
www.iowamedicaidpdl.com
maximum Yorvipath® dosage, consider adding or restarting calcium and/or active vitamin D therapy and/or seek other treatment options. • Yorvipath's® once ...
www.iowamedicaidpdl.com
maximum Yorvipath® dosage, consider adding or restarting calcium and/or active vitamin D therapy and/or seek other treatment options. • Yorvipath's® once ...
Yorvipath® / Minnesota Department of Human Services - MN.gov
mn.gov
Jun 16, 2025 ... Drug - Yorvipath® (palopegteriparatide injection) [Ascendis Pharma Endocrinology, Inc.] June 2025. Therapeutic Area - Hyperparathyroid Agents ...
mn.gov
Jun 16, 2025 ... Drug - Yorvipath® (palopegteriparatide injection) [Ascendis Pharma Endocrinology, Inc.] June 2025. Therapeutic Area - Hyperparathyroid Agents ...
216490Orig1s000 LABELING - accessdata.fda.gov
www.accessdata.fda.gov
Aug 9, 2024 ... seek other treatment options [see Warnings and ... YORVIPATH-treated patients) had low titer treatment-emergent antibodies against PEG.
www.accessdata.fda.gov
Aug 9, 2024 ... seek other treatment options [see Warnings and ... YORVIPATH-treated patients) had low titer treatment-emergent antibodies against PEG.